BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8935564)

  • 1. [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients].
    Roldan EJ; Kerzberg EM; Castelli G; Lloret AP
    Medicina (B Aires); 1996; 56(2):133-7. PubMed ID: 8935564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New spine and non-spine fractures in 871 women/year treated with oral pamidronate plus calcium and vitamin D supplements].
    Man Z; Otero AB
    Medicina (B Aires); 1997; 57 Suppl 1():32-6. PubMed ID: 9567352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclical pamidronate infusions in postmenopausal osteoporosis.
    Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
    Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women.
    Mastaglia SR; Mautalen CA; Parisi MS; Oliveri B
    Eur J Clin Nutr; 2006 May; 60(5):681-7. PubMed ID: 16391587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
    Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
    Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.
    Landman JO; Schweitzer DH; Frölich M; Hamdy NA; Papapoulos SE
    J Clin Endocrinol Metab; 1995 Feb; 80(2):524-8. PubMed ID: 7852514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate.
    Cheng PT; Chan C; Müller K
    J Bone Miner Res; 1995 Jan; 10(1):119-26. PubMed ID: 7747618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
    Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
    J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of anticonvulsant drug-induced bone disease.
    Drezner MK
    Epilepsy Behav; 2004 Feb; 5 Suppl 2():S41-7. PubMed ID: 15123011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study.
    Piemonte S; Romagnoli E; Cipriani C; Fassino V; Del Fiacco R; Carnevale V; Scillitani A; D'Erasmo E; Tancredi A; Minisola S
    Calcif Tissue Int; 2009 Oct; 85(4):287-92. PubMed ID: 19756348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate].
    González D; Pastrana M; Mautalen C
    Medicina (B Aires); 1997; 57 Suppl 1():25-31. PubMed ID: 9567351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial.
    Jafarnejad S; Djafarian K; Fazeli MR; Yekaninejad MS; Rostamian A; Keshavarz SA
    J Am Coll Nutr; 2017; 36(7):497-506. PubMed ID: 28628374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clodronic acid in the treatment of postmenopausal osteoporosis.
    Tanakol R; Yarman S; Bayraktaroglu T; Boztepe H; Alagöl F
    Clin Drug Investig; 2007; 27(6):419-33. PubMed ID: 17506592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction.
    Yendt ER; Kovacs KA; Jones G
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):855-63. PubMed ID: 18419790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral therapy with calcium and vitamin D in primary osteoporosis.
    Riggs BL; Jowsey J; Kelly PJ; Hoffman DL; Arnaud CD
    J Clin Endocrinol Metab; 1976 Jun; 42(6):1139-44. PubMed ID: 932176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.